Davies N M, Saleh J Y, Skjodt N M
Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia.
J Pharm Pharm Sci. 2000 Jan-Apr;3(1):137-55.
Non-steroidal anti-inflammatory drugs (NSAIDs) may cause damage distal to the duodenum. We reviewed the prevalence, clinical spectrum, assessment, pathogenesis, and treatment of adverse effects of NSAIDs on the small intestine. NSAIDs can cause small intestinal perforation, ulcers, and strictures requiring surgery. NSAIDs produce inflammation of the small intestine in 40 to 70% in long-term users, and the associated complications of blood loss and protein loss are difficult management problems. The pathogenesis of NSAID enteropathy is a multi-stage process involving specific biochemical and subcellular organelle damage followed by inflammatory tissue reaction. Various suggested treatments of NSAID-induced enteropathy (e.g., sulphasalazine, misoprostol, and metronidazole) have yet to undergo rigorous clinical trials. Cyclo-oxygenase-2 inhibitors appear to be safer to the small intestine than traditional NSAIDs. Pre-clinical and clinical data suggests meloxicam, celecoxib, nimesulide and rofecoxib may have less small intestine toxicity than traditional non-selective NSAIDs.
非甾体抗炎药(NSAIDs)可能会导致十二指肠远端受损。我们回顾了NSAIDs对小肠不良反应的发生率、临床谱、评估、发病机制及治疗。NSAIDs可导致小肠穿孔、溃疡及需要手术治疗的狭窄。长期使用NSAIDs的患者中,40%至70%会出现小肠炎症,而与之相关的失血和蛋白质丢失并发症是难以处理的问题。NSAID小肠病的发病机制是一个多阶段过程,涉及特定的生化和亚细胞器损伤,随后是炎症组织反应。各种针对NSAID诱导小肠病的建议治疗方法(如柳氮磺胺吡啶、米索前列醇和甲硝唑)尚未经过严格的临床试验。环氧化酶-2抑制剂对小肠似乎比传统NSAIDs更安全。临床前和临床数据表明,美洛昔康、塞来昔布、尼美舒利和罗非昔布对小肠的毒性可能比传统非选择性NSAIDs小。